Topical loperamide
This article was originally published in The Tan Sheet
Executive Summary
SmithKline Beecham and Adolor sign licensing agreement for worldwide (excluding Korea) prescription and OTC development and commercial rights to the topical dermal ingredient ADL 2-1294 (loperamide) used for the treatment of inflammatory pain and itching. If multiple indications for the ingredient are found, Adolor will receive up to $48 mil. from development payments as well as a licensing fee and equity investment from SmithKline. Loperamide is sold as an OTC oral antidiarrhea. The reference product is McNeil Consumer Healthcare's Imodium